ARV-7: A biomarker for the treatment of metastatic castration-resistant prostate cancer.
- Author:
Ze-Yu CHEN
1
;
Qiang DONG
1
;
Liang-Ren LIU
1
;
Qiang WEI
1
Author Information
1. Research Institute of Urology / Department of Urology, West China Hospital, Sichuan University, Chengdu, Sichuan 610041, China.
- Publication Type:Journal Article
- Keywords:
androgen receptor;
androgen receptor splice variant 7;
castration-resistant prostate cancer
- From:
National Journal of Andrology
2019;25(2):172-176
- CountryChina
- Language:Chinese
-
Abstract:
As more and more patients with metastatic prostate cancer develop resistance to androgen-deprivation therapy (ADT) and consequently castration-resistant prostate cancer (CRPC), reasonable selection of therapies is becoming increasingly important for the prediction of the therapeutic results. Many studies show that androgen receptor splice variant 7 (AR-V7) is involved in the development and progression of CRPC and that the expression of AR-V7, absolutely higher in CRPC than in hormone-nave prostate cancer, plays a significant role in the mechanisms of resistance to abiraterone, enzalutamide and taxane chemotherapies. Further more, some clinical trials have revealed that the AR-V7 level may indicate the prognosis of different therapeutic options: AR-V7 negative in circulating tumor cells suggesting the effectiveness of a new hormonal therapy and taxane chemotherapy while AR-V7 positive indicating the poor result of a new hormonal therapy. These findings show that AR-V7 could be a biomarker for therapeutic options and the prognostic evaluation of CRPC.
